Fluoroquinolone, the second-line TB drug, targets a DNA gyrase encoded by gyrA and gyrB. Like rifampin’s rpoB hotspot, drug resistance to fluoroquinolone is also associated with specific mutations in the quinolone resistance-determining region (QRDR) of gyrA & gyrB45. Here, TOP2A is linked to tuberculosis.